沙库巴曲缬沙坦钠片与缬沙坦片治疗慢性心衰的疗效对比

Comparison of the efficacy of sacubatre valsartan sodium tablets and valsartan tablets in the treatment of chronic heart failure

目的对比沙库巴曲缬沙坦钠片与缬沙坦片治疗慢性心力衰竭(心衰)的疗效。方法100例慢性心衰患者,采用随机数字表法分为对照组和观察组,每组50例。对照组患者给予缬沙坦片治疗,观察组患者给予沙库巴曲缬沙坦钠片治疗。比较两组血压控制正常时间、心功能分级降低2级时间,治疗前后血压、心功能指标水平,临床疗效,不良反应发生情况。结果观察组患者的血压控制正常时间、心功能分级降低2级时间分别为(7.24±1.20)、(8.41±2.21)d,均短于对照组的(9.34±2.48)、(11.45±3.21)d,差异具有统计学意义(P<0.05)。治疗后,两组舒张压、收缩压、舒张期室间隔厚度、舒张期左室后壁厚度、左室射血分数、左室舒张末期内径和左室收缩末期内径均较治疗前改善,且观察组舒张压(76.20±3.25)mm Hg(1 mm Hg=0.133 kPa)、收缩压(122.24±2.01)mm Hg、舒张期室间隔厚度(8.01±0.23)mm、舒张期左室后壁厚度(8.23±0.12)mm、左室射血分数(57.41±4.21)%、左室收缩末期内径(40.12±1.45)mm和左室舒张末期内径(45.21±2.12)mm均显著优于对照组的(84.21±4.51)mm Hg、(131.14±2.13)mm Hg、(9.16±0.51)mm、(9.33±0.31)mm、(47.20±3.31)%、(44.56±1.52)mm、(51.21±2.56)mm,差异具有统计学意义(P<0.05)。观察组患者的治疗总有效率96.00%高于对照组的80.00%,差异具有统计学意义(P<0.05)。两组均未发生严重不良反应。结论沙库巴曲缬沙坦钠片对于慢性心衰的治疗效果优于缬沙坦片,可更好的控制血压,逆转心衰,促进心室重塑,值得推广。

Objective To compare the efficacy of sacubatre valsartan sodium tablets and valsartan tablets in the treatment of chronic heart failure.Methods A total of 100 patients with chronic heart failure were randomly divided into control group and observation group by random numerical table,with 50 cases in each group.Patients in the control group were treated with valsartan tablets,and patients in the observation group were treated with sacubitril valsartan sodium tablets.Both groups were compared in terms of recovery time of blood pressure,time for reduction of cardiac function classification by 2 grades,blood pressure and cardiac function indexes before and after treatment,clinical efficacy,and occurrence of adverse reactions.Results The recovery time of blood pressure and time for reduction of cardiac function classification by 2 grades in the observation group were(7.24±1.20)and(8.41±2.21)d,which were shorter than(9.34±2.48)and(11.45±3.21)d in the control group,and the differences were statistically significant(P<0.05).After treatment,the diastolic blood pressure,systolic blood pressure,interventricular septum thickness at diastole,left ventricular posterior wall thickness at diastole,left ventricular ejection fraction,left ventricular end-diastolic diameter and left ventricular endsystolic diameter in the two groups were all improved compared with those before treatment in this group;in the observation group,the diastolic blood pressure was(76.20±3.25)mm Hg(1 mm Hg=0.133 kPa),the systolic blood pressure was(122.24±2.01)mm Hg,the interventricular septum thickness at diastole was(8.01±0.23)mm,the left ventricular posterior wall thickness at diastole was(8.23±0.12)mm,the left ventricular ejection fraction was(57.41±4.21)%,the left ventricular end-systolic diameter was(40.12±1.45)mm and the left ventricular enddiastolic diameter(45.21±2.12)mm,which were significantly better than(84.21±4.51)mm Hg,(131.14±2.13)mm Hg,(9.16±0.51)mm,(9.33±0.31)mm,(47.20±3.31)%,(44.56±1.52)mm,(51.21±2.56)mm in the control group;all the differences were statistically significant(P<0.05).The total effective rate 96.00%of the observation group was higher than 80.00%of the control group,and the difference was statistically significant(P<0.05).There were no serious adverse reactions in the two groups.Conclusion Sacubatre valsartan sodium tablets have better therapeutic effect than valsartan tablets on chronic heart failure,and can better control blood pressure, reverse heart failure, and promote ventricular remodeling, which is worthy of promotion .